Whole genome protein microarrays for serum profiling of immunodominant antigens of Bacillus anthracis

Frontiers in Microbiology
Karen E KempsellRichard Vipond

Abstract

A commercial Bacillus anthracis (Anthrax) whole genome protein microarray has been used to identify immunogenic Anthrax proteins (IAP) using sera from groups of donors with (a) confirmed B. anthracis naturally acquired cutaneous infection, (b) confirmed B. anthracis intravenous drug use-acquired infection, (c) occupational exposure in a wool-sorters factory, (d) humans and rabbits vaccinated with the UK Anthrax protein vaccine and compared to naïve unexposed controls. Anti-IAP responses were observed for both IgG and IgA in the challenged groups; however the anti-IAP IgG response was more evident in the vaccinated group and the anti-IAP IgA response more evident in the B. anthracis-infected groups. Infected individuals appeared somewhat suppressed for their general IgG response, compared with other challenged groups. Immunogenic protein antigens were identified in all groups, some of which were shared between groups whilst others were specific for individual groups. The toxin proteins were immunodominant in all vaccinated, infected or other challenged groups. However, a number of other chromosomally-located and plasmid encoded open reading frame proteins were also recognized by infected or exposed groups in comparison to contro...Continue Reading

References

Aug 1, 1991·Vaccine·P C Turnbull
Jan 1, 1983·Infection and Immunity·P MikesellT M Dreier
Apr 1, 1996·The Journal of Experimental Medicine·K FujihashiH Kiyono
Dec 5, 1997·Current Topics in Microbiology and Immunology·P Hanna
Sep 9, 1999·The New England Journal of Medicine·T C DixonP C Hanna
Dec 14, 1999·Microbes and Infection·S F Little, B E Ivins
Feb 15, 2001·Current Opinion in Microbiology·L Baillie, T D Read
Dec 19, 2001·Emerging Infectious Diseases·J A JerniganUNKNOWN Anthrax Bioterrorism Investigation Team
Mar 2, 2002·Journal of Medical Microbiology·S J DancerA B Kolsto
Oct 25, 2002·Emerging Infectious Diseases·Bradley A PerkinsKevin Yeskey
Oct 25, 2002·Emerging Infectious Diseases·Daniel B JerniganUNKNOWN National Anthrax Epidemiologic Investigation Team
Oct 25, 2002·Emerging Infectious Diseases·Carolyn M GreeneUNKNOWN CDC New Jersey Anthrax Investigation Team. Centers for Desease Control and Prevention
Oct 25, 2002·Emerging Infectious Diseases·Puneet K DewanUNKNOWN Washington, D.C., Anthrax Response Team
Jun 7, 2005·Advanced Drug Delivery Reviews·Robert N Brey
Jun 28, 2005·Annals of Saudi Medicine·Miroslav SplinoRoman Chlibek
Sep 1, 2005·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Stephen F Little
May 4, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Hui FangDavid M Frucht
Jul 25, 2006·Trends in Immunology·Cosima T BaldariCesare Montecucco
Dec 28, 2006·The Journal of Infectious Diseases·James L Hadler
Jan 25, 2008·Proceedings of the National Academy of Sciences of the United States of America·Claudia R OlivaJohn F Kearney
Mar 11, 2008·Cell Host & Microbe·Ruslana BrykCarl Nathan
Apr 21, 2009·Analytical and Bioanalytical Chemistry·Jan Weile, Cornelius Knabbe
May 23, 2009·Vaccine·Christian SøborgBen van der Zeijst
Aug 12, 2009·Proceedings of the National Academy of Sciences of the United States of America·Philip L FelgnerRichard W Titball
Oct 20, 2009·Vaccine·Arthur M Friedlander, Stephen F Little
Oct 29, 2009·Emerging Infectious Diseases·Pierre WattiauGermaine Hanquet
Apr 20, 2010·Journal of Microbiological Methods·Shilpakala Sainath RaoChintamani D Atreya
Apr 20, 2010·Lancet·Malcolm G BoothUNKNOWN Health Protection Scotland Anthrax Clinical Network
Apr 22, 2010·Methods in Molecular Biology·Barry SchweitzerAlex J Rai
Sep 22, 2010·Methods in Molecular Biology·Marina CretichMarcella Chiari
Oct 22, 2010·Trends in Biotechnology·Sandeep J Joseph, Timothy D Read
Jan 6, 2011·Archives of Pathology & Laboratory Medicine·Juan P Olano, David H Walker
Mar 16, 2011·FEMS Immunology and Medical Microbiology·Karen E BrennemanLeslie W Baillie
May 24, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Norah E PalmateerSharon J Hutchinson
Jul 31, 2012·Emerging Infectious Diseases·Erin P PricePaul Keim
Feb 5, 2013·The Journal of Laryngology and Otology·S MeghjiE Carr
Jul 16, 2013·The Journal of Immunology : Official Journal of the American Association of Immunologists·Shijuan Grace ZengDerek G Doherty
Sep 6, 2013·BMC Infectious Diseases·Lene RussellAnn-Brit Eg Hansen
Sep 21, 2013·The Journal of Clinical Investigation·Amanda S MacLeodWendy L Havran

❮ Previous
Next ❯

Citations

Jul 31, 2020·Expert Opinion on Biological Therapy·Manish ManishRakesh Bhatnagar
Mar 23, 2021·World Journal of Microbiology & Biotechnology·Abhinay SharmaAtul Kumar Johri

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
ELISA
ELISAs

Software Mentioned

Softmax Pro
R
SigmaPlot
tBLASTn
BLAST
BLASTP
Anthrax ProtoArray
Agilent GeneSpring
GX
Systat

Related Concepts

Related Feeds

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.